- Home
- HEPS vs GYRE Comparison
HEPS vs GYRE Comparison
Compare HEPS & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPS
- GYRE
- Stock Information
- Founded
- HEPS 2000
- GYRE 2002
- Country
- HEPS Turkey
- GYRE United States
- Employees
- HEPS N/A
- GYRE N/A
- Industry
- HEPS Catalog/Specialty Distribution
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- HEPS Consumer Discretionary
- GYRE Health Care
- Exchange
- HEPS Nasdaq
- GYRE Nasdaq
- Market Cap
- HEPS 870.4M
- GYRE 755.7M
- IPO Year
- HEPS 2021
- GYRE N/A
- Fundamental
- Price
- HEPS $2.27
- GYRE $7.65
- Analyst Decision
- HEPS
- GYRE Strong Buy
- Analyst Count
- HEPS 0
- GYRE 2
- Target Price
- HEPS N/A
- GYRE $17.00
- AVG Volume (30 Days)
- HEPS 254.7K
- GYRE 61.5K
- Earning Date
- HEPS 11-05-2025
- GYRE 11-07-2025
- Dividend Yield
- HEPS N/A
- GYRE N/A
- EPS Growth
- HEPS N/A
- GYRE N/A
- EPS
- HEPS N/A
- GYRE 0.04
- Revenue
- HEPS $1,504,533,586.00
- GYRE $107,265,000.00
- Revenue This Year
- HEPS $37.91
- GYRE $15.25
- Revenue Next Year
- HEPS $28.48
- GYRE $33.14
- P/E Ratio
- HEPS N/A
- GYRE $204.90
- Revenue Growth
- HEPS 56.77
- GYRE 2.13
- 52 Week Low
- HEPS $2.15
- GYRE $6.11
- 52 Week High
- HEPS $3.85
- GYRE $14.42
- Technical
- Relative Strength Index (RSI)
- HEPS 33.99
- GYRE 46.02
- Support Level
- HEPS $2.15
- GYRE $7.82
- Resistance Level
- HEPS $2.34
- GYRE $8.47
- Average True Range (ATR)
- HEPS 0.10
- GYRE 0.35
- MACD
- HEPS -0.01
- GYRE -0.00
- Stochastic Oscillator
- HEPS 26.24
- GYRE 34.07
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.